What medication can be given for prolonged menses in a patient on birth control?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Prolonged Menses in Patients on Birth Control

For a patient on birth control experiencing prolonged menstrual bleeding, first-line treatment is NSAIDs (ibuprofen or naproxen) for 5-7 days during bleeding episodes, with short-term hormonal therapy (low-dose combined oral contraceptives containing 30-35 μg ethinyl estradiol or estrogen alone for 10-20 days) as an alternative if NSAIDs are insufficient or the patient is medically eligible. 1, 2

Initial Assessment Before Treatment

Before initiating any medication, you must rule out underlying pathology that could be causing the bleeding 1, 2:

  • Pregnancy - Always exclude this first 1, 2
  • Sexually transmitted infections - Particularly important in reproductive-aged women 2
  • Medication interactions - Check if other drugs are interfering with contraceptive efficacy 1
  • New pathologic uterine conditions - Such as polyps or fibroids 1

If any underlying gynecological problem is identified, treat that condition or refer for specialized care before addressing the bleeding symptomatically 1.

First-Line Medical Treatment

NSAIDs (Preferred Initial Option)

NSAIDs for 5-7 days during bleeding episodes are the recommended first-line treatment 1, 2:

  • Use during active bleeding days only 1, 2
  • Examples include ibuprofen or naproxen 1
  • This approach reduces menstrual blood flow acutely 2
  • Well-tolerated with minimal side effects 1

Short-Term Hormonal Therapy (If NSAIDs Insufficient)

If NSAIDs alone don't control bleeding and the patient is medically eligible, add hormonal treatment 1, 2:

  • Low-dose combined oral contraceptives containing 30-35 μg ethinyl estradiol for 10-20 days 1, 2
  • Alternatively, estrogen alone for 10-20 days can be used 1
  • This is appropriate even if the patient is already on hormonal contraception 1

Important caveat: Before prescribing additional estrogen-containing therapy, assess for thrombotic risk factors, as combined oral contraceptives increase venous thromboembolism risk three to fourfold 2.

Special Considerations for Extended/Continuous Regimens

If the patient is using extended or continuous combined oral contraceptive regimens 2, 3:

  • Consider a hormone-free interval of 3-4 consecutive days to temporarily induce bleeding and thin the endometrium 2, 3
  • Do NOT use this approach during the first 21 days of the extended/continuous regimen 2, 3
  • Do NOT use more than once per month 2, 3

Counseling and Reassurance

Provide reassurance that unscheduled bleeding is common during hormonal contraceptive use 1, 2:

  • Spotting and irregular bleeding are particularly common in the first 3-6 months of hormonal therapy 2
  • These bleeding changes are generally not harmful 1, 2
  • Enhanced counseling about expected bleeding patterns reduces discontinuation rates 1

When to Consider Alternative Contraceptive Methods

If bleeding persists despite treatment and the patient finds it unacceptable 1, 2:

  • Counsel on alternative contraceptive methods 1, 2
  • Offer another method if desired 1, 2
  • Options might include switching to a different hormonal formulation or considering the levonorgestrel-releasing intrauterine system 4

Follow-Up

No routine follow-up visit is required 1, 2:

  • Advise the patient to return if side effects develop or concerns arise 1, 2
  • If follow-up occurs, assess satisfaction with the method and any health status changes 1, 2
  • Monitor blood pressure at follow-up visits for patients on combined oral contraceptives 2

What NOT to Use

Avoid oral progestogens (medroxyprogesterone acetate or norethisterone) for this indication 5, 6:

  • The FDA label specifically states that injectable medroxyprogesterone acetate "is not recommended in secondary amenorrhea or dysfunctional uterine bleeding" due to its prolonged action and difficulty predicting withdrawal bleeding 5
  • Research shows short-cycle luteal phase progestogens are inferior to other medical therapies for reducing menstrual blood loss 6
  • Long-cycle progestogens (day 5-26) are also inferior to other treatments 6

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Prolonged Menstrual Bleeding

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Heavy Menstrual Bleeding in Adolescents

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Cyclical progestogens for heavy menstrual bleeding.

The Cochrane database of systematic reviews, 2019

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.